• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Caym. Inds·Consumer Cyclical·BON
Share

Bon Natural Life Limited Stocks

$ 1.28Last Updated 26.05.2026

Issuer Rating

2/7
Performance

Average

Risk

Critical

Recommendation

Sell

Market Cap

$ 7.73M

$ 1.28
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is neutral on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.05.2026 23:51

JPMorgan in search of a big deal: Dimon admits to a takeover worth up to $20 billion

27.05.2026 23:18

Has the energy shock reached Europe? Britons' energy costs set to soar to a two-year peak

27.05.2026 22:34

'Turning point': Lululemon settles dispute with founder. What about the stock?

27.05.2026 20:26

Michael Kors owner expects profit growth at the expense of youth. What about the stock?

27.05.2026 19:25

Goldman predicted a 17% rise in the S&P 500 in 2026. Why did it improve its forecast?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026